Treatment

Recent advances in muscle-invasive bladder cancer (MIBC) have expanded treatment options, particularly for high-risk and metastatic disease. Combination therapy with Enfortumab vedotin and Pembrolizumab is now a first-line option for advanced bladder cancer. Enfortumab vedotin delivers chemotherapy directly to tumor cells, while pembrolizumab activates the immune system to recognize and attack cancer. Adjuvant immunotherapy with […]

The combination of Nivolumab and Ipilimumab is a groundbreaking immunotherapy that helps the immune system attack cancer. Ipilimumab “primes” T-cells by blocking the early CTLA-4 checkpoint, allowing more immune cells to prepare for action, while nivolumab “unleashes” them by inhibiting the PD-1 checkpoint, preventing cancer cells from hiding. Together, they create a powerful, synergistic immune

Pembrolizumab is a pioneering checkpoint inhibitor that empowers the immune system to fight cancer by blocking PD-1 receptors on T-cells. Normally, cancer cells exploit PD-L1 to turn off T-cells, evading immune attack. Pembrolizumab removes this “brake,” allowing T-cells to recognize and destroy tumors. This approach shifts cancer therapy from directly targeting cells to enhancing the

Taletrectinib (Ibtrozi) is a newly FDA-approved treatment for ROS1-positive non-small cell lung cancer (NSCLC), a rare subtype driven by ROS1 gene rearrangements. These fusions promote tumor growth, making them highly responsive to targeted therapy. Taletrectinib is a next-generation oral ROS1 inhibitor with high potency, selectivity, and the ability to cross the blood-brain barrier. It works

TAR-200 is an investigational device that delivers gemcitabine chemotherapy directly into the bladder for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer. The pretzel-shaped system is inserted via catheter and releases the drug over three weeks per cycle. It can be used alone or with cetrelimab, a PD-1 inhibitor, for patients who cannot or refuse to

Bispecific antibodies are an emerging cancer treatment that can attach to two targets at once, making them more precise and powerful than traditional antibodies. One arm of the antibody may bind to cancer cells while the other connects T-cells, directing the immune system to attack tumors even when T-cells don’t naturally recognize them. Some bispecifics

Invikafusp alfa is a novel immunotherapy showing promise for advanced colorectal cancer, especially in patients resistant to PD-1 inhibitors. Developed by Marengo Therapeutics, it is a selective dual T-cell agonist that activates and expands specific T cells (Vβ6 and Vβ10), boosting the immune system’s ability to attack cancer cells. Unlike PD-1 inhibitors, which release immune

Triple-negative breast cancer (TNBC) is an aggressive disease that lacks estrogen, progesterone, and HER2 receptors, making standard targeted therapies ineffective. For years, chemotherapy was the primary treatment. Recently, combination approaches have improved outcomes by attacking tumors from multiple angles. One key strategy combines immunotherapy with chemotherapy. TNBC tumors often express PD-L1, helping them evade immune

Combination therapy has transformed treatment for advanced thyroid cancers, especially aggressive anaplastic thyroid cancer (ATC) and radioiodine-refractory differentiated thyroid cancer (DTC). By targeting multiple pathways at once, these approaches overcome resistance and significantly improve patient outcomes compared with traditional single therapies. A major advance is the FDA-approved combination of dabrafenib and trametinib for BRAF V600E–mutated

Zusduri is the first FDA-approved targeted, non-surgical treatment for recurrent low-grade, intermediate-risk non–muscle invasive bladder cancer. It delivers mitomycin C directly into the bladder using RTGel® technology, which turns from liquid to gel at body temperature. This allows the drug to stay in contact with the bladder wall for hours, maximizing local effect while minimizing